US5232929A
(en)
|
1990-11-28 |
1993-08-03 |
Pfizer Inc. |
3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
|
US5364943A
(en)
*
|
1991-11-27 |
1994-11-15 |
Pfizer Inc. |
Preparation of substituted piperidines
|
EP1082959A1
(en)
|
1991-09-20 |
2001-03-14 |
Glaxo Group Limited |
NK1 Antagonists for the treatment of depression
|
WO1993023380A1
(en)
*
|
1992-05-18 |
1993-11-25 |
Pfizer Inc. |
Bridged aza-bicyclic derivatives as substance p antagonists
|
US5688804A
(en)
*
|
1992-08-04 |
1997-11-18 |
Pfizer Inc. |
3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
|
ATE208376T1
(de)
*
|
1992-08-19 |
2001-11-15 |
Pfizer |
Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
|
ES2147759T3
(es)
*
|
1992-12-10 |
2000-10-01 |
Pfizer |
Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
|
FR2700472B1
(fr)
|
1993-01-19 |
1995-02-17 |
Rhone Poulenc Rorer Sa |
Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
|
US5340826A
(en)
*
|
1993-02-04 |
1994-08-23 |
Pfizer Inc. |
Pharmaceutical agents for treatment of urinary incontinence
|
US5635510A
(en)
*
|
1993-05-06 |
1997-06-03 |
Merrell Pharmaceuticals Inc. |
Substituted pyrrolidin-3-yl-alkyl-piperidines
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
EP0653208A3
(en)
*
|
1993-11-17 |
1995-10-11 |
Pfizer |
Substance P antagonists for the treatment or prevention of sunburn.
|
EP0659409A3
(en)
*
|
1993-11-23 |
1995-08-09 |
Pfizer |
Substance P antagonists for the inhibition of angiogenesis.
|
EP0655246A1
(en)
*
|
1993-11-30 |
1995-05-31 |
Pfizer Inc. |
Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
|
CA2198084C
(en)
|
1994-08-25 |
2000-03-28 |
Timothy P. Burkholder |
Novel substituted piperidines useful for the treatment of allergic diseases
|
FR2728165A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
FR2728166A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Composition topique contenant un antagoniste de substance p
|
FR2728169A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
|
JP3950170B2
(ja)
*
|
1995-04-13 |
2007-07-25 |
アベンティス・ファーマスーティカルズ・インコーポレイテッド |
タキキニン受容体アンタゴニスト活性を有する新規な置換されたピペラジン誘導体
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
US6211199B1
(en)
|
1995-11-17 |
2001-04-03 |
Aventis Pharmaceuticals Inc. |
Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
|
FR2741262B1
(fr)
|
1995-11-20 |
1999-03-05 |
Oreal |
Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
|
US6194406B1
(en)
|
1995-12-20 |
2001-02-27 |
Aventis Pharmaceuticals Inc. |
Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
|
US6423704B2
(en)
|
1995-12-20 |
2002-07-23 |
Aventis Pharmaceuticals Inc. |
Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
|
US5922737A
(en)
*
|
1996-02-21 |
1999-07-13 |
Hoechst Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
|
US5998439A
(en)
*
|
1996-02-21 |
1999-12-07 |
Hoescht Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
|
US5932571A
(en)
*
|
1996-02-21 |
1999-08-03 |
Hoechst Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
|
CA2324116A1
(en)
*
|
1999-10-25 |
2001-04-25 |
Susan Beth Sobolov-Jaynes |
Nk-1 receptor antagonists and eletriptan for the treatment of migraine
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
JP4907818B2
(ja)
|
1999-11-03 |
2012-04-04 |
エーエムアール テクノロジー インコーポレイテッド |
アリールおよびヘテロアリール置換テトラヒドロイソキノリン、ならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを阻止するためのそれらの使用
|
DE60112064T2
(de)
*
|
2000-04-10 |
2006-06-01 |
Pfizer Products Inc., Groton |
Benzoamid-piperidin verbindungen als substanz p-antagonisten
|
US7119207B2
(en)
*
|
2000-04-10 |
2006-10-10 |
Pfizer Inc |
Benzoamide piperidine containing compounds and related compounds
|
CN100430401C
(zh)
|
2000-07-11 |
2008-11-05 |
Amr科技公司 |
新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
|
US20020049211A1
(en)
*
|
2000-09-06 |
2002-04-25 |
Sobolov-Jaynes Susan Beth |
Combination treatment for depression and anxiety
|
EP1192952A3
(en)
*
|
2000-09-28 |
2003-03-26 |
Pfizer Products Inc. |
Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
|
WO2006020049A2
(en)
|
2004-07-15 |
2006-02-23 |
Amr Technology, Inc. |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
ES2336130T3
(es)
*
|
2004-10-18 |
2010-04-08 |
Eli Lilly And Company |
Derivados 1-(hetero)aril-3-amino-pirrolidina para uso como antagonistas del receptor de mglur3.
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
KR101589551B1
(ko)
|
2005-07-15 |
2016-02-02 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
CN101277960A
(zh)
|
2005-09-29 |
2008-10-01 |
默克公司 |
作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8173629B2
(en)
|
2006-09-22 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
RS58936B1
(sr)
|
2007-01-10 |
2019-08-30 |
Msd Italia Srl |
Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US8598184B2
(en)
|
2008-03-03 |
2013-12-03 |
Tiger Pharmatech |
Protein kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
EP2429293B1
(en)
|
2009-05-12 |
2014-10-29 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
CA2760837C
(en)
|
2009-05-12 |
2018-04-03 |
Albany Molecular Research, Inc. |
7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
|
KR20120034644A
(ko)
|
2009-05-12 |
2012-04-12 |
알바니 몰레큘라 리써치, 인크. |
아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
|
CN104945382B
(zh)
|
2009-10-14 |
2020-02-07 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
WO2012018754A2
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US9029341B2
(en)
|
2010-08-17 |
2015-05-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
WO2014078568A1
(en)
|
2012-11-14 |
2014-05-22 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
WO2014085216A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
EP3833668A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
EP3986886A2
(en)
*
|
2019-06-19 |
2022-04-27 |
Grünenthal GmbH |
Substituted pyrrolidine amides v
|